MADCAM1 and inflammatory bowel disease: MAdCAM-1 is upregulated in inflammatory bowel diseases (IBDs), and blocking the α4β7/MAdCAM-1 interaction with vedolizumab, a humanized monoclonal antibody to α4β7, is an effective therapeutic for IBDs (13).